Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TY. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet. 2022 ;399:729-40.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. The Lancet. 2022 ;399:741-55.
Mohammad, N. (2021). The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). Iraqi Postgraduate Medical Journal, 21(4), 373-373. doi: 10.52573/ipmj.2021.176975
MLA
Najah K. Mohammad. "The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)". Iraqi Postgraduate Medical Journal, 21, 4, 2021, 373-373. doi: 10.52573/ipmj.2021.176975
HARVARD
Mohammad, N. (2021). 'The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)', Iraqi Postgraduate Medical Journal, 21(4), pp. 373-373. doi: 10.52573/ipmj.2021.176975
VANCOUVER
Mohammad, N. The Use of Faricimab for the Treatment of Wet age Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). Iraqi Postgraduate Medical Journal, 2021; 21(4): 373-373. doi: 10.52573/ipmj.2021.176975
)
